{"id":31281,"date":"2026-03-13T08:46:56","date_gmt":"2026-03-13T08:46:56","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/31281\/"},"modified":"2026-03-13T08:46:56","modified_gmt":"2026-03-13T08:46:56","slug":"roche-breast-cancer-drug-combination-misses-target-in-study","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/31281\/","title":{"rendered":"Roche Breast-Cancer Drug Combination Misses Target in Study"},"content":{"rendered":"<p class=\"ArticleBodyText_articleBodyContent__17wqE typography_articleBody___5jDr\" data-component=\"paragraph\"><a href=\"https:\/\/www.bloomberg.com\/quote\/ROG:SW\" target=\"_blank\" rel=\"noopener nofollow\" class=\"media-ui-Link_link-tVkXhPLPofs-\" data-component=\"link\">Roche Holding AG<\/a>\u2019s experimental breast-cancer pill failed to meet the main goal of a study, a blow to the drugmaker\u2019s efforts to develop a next-generation hormone therapy that caused the shares to plunge.<\/p>\n<p class=\"ArticleBodyText_articleBodyContent__17wqE typography_articleBody___5jDr\" data-component=\"paragraph\">Patients treated with Roche\u2019s giredestrant and an older drug developed by <a href=\"https:\/\/www.bloomberg.com\/quote\/PFE:US\" target=\"_blank\" rel=\"noopener nofollow\" class=\"media-ui-Link_link-tVkXhPLPofs-\" data-component=\"link\">Pfizer Inc.<\/a> were no more likely to live without their cancer worsening than those given standard therapy, the Swiss drugmaker <a href=\"https:\/\/www.bloomberg.com\/news\/terminal\/TBMBC0TP3SHV\" class=\"media-ui-Link_link-tVkXhPLPofs- whitespace-normal\" target=\"_blank\" rel=\"noopener nofollow\" data-component=\"link\">said MondayBloomberg Terminal<\/a>. <\/p>\n","protected":false},"excerpt":{"rendered":"Roche Holding AG\u2019s experimental breast-cancer pill failed to meet the main goal of a study, a blow to&hellip;\n","protected":false},"author":2,"featured_media":31282,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[124],"tags":[2350,2112,17124,6107,10622,2349,304,3310,134,13222,17,3612],"class_list":{"0":"post-31281","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-roche","8":"tag-astrazeneca-plc","9":"tag-cancer","10":"tag-design","11":"tag-great-britain","12":"tag-industries","13":"tag-pfizer-inc","14":"tag-pharmaceutical","15":"tag-regulation","16":"tag-roche","17":"tag-roche-holding-ag-genusschein","18":"tag-switzerland","19":"tag-women"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116221001292216929","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/31281","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=31281"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/31281\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/31282"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=31281"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=31281"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=31281"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}